BlackRock Health Sciences Term Trust

This committee provides the official 'revenue estimates' for all tax bills and influences corporate tax structures, capital investment credits, and the overall tax burden, directly impacting the profitability and financial strategies of health sciences companies and BlackRock itself.

This powerful committee controls taxation, trade, and entitlement spending (like Medicare). It directly influences corporate valuations through tax policy and impacts the healthcare sector through Medicare pricing and reimbursement policies, making it highly relevant to health sciences investments.

This committee's subcommittees allocate discretionary federal spending, directly determining funding levels for critical scientific research (e.g., NIH, CDC), public health initiatives, and government healthcare programs, profoundly impacting revenue for health sciences companies.

This committee directly regulates the FDA and NIH, which are primary drivers of stock performance in the pharmaceutical and biotech sectors through drug approval oversight, R&D funding, and public health policy, making it highly relevant to health sciences.

Oversight of antitrust laws and intellectual property is paramount for the pharmaceutical and biotech industries, impacting M&A activity, drug patents, and competitive landscapes within the health sciences sector.

This committee investigates critical issues affecting older Americans, such as drug pricing and long-term care quality, creating significant 'headline risk' and potential for future regulation impacting pharmaceutical companies and healthcare providers, core to health sciences.

This committee directly regulates BlackRock as a financial institution and asset manager, overseeing investment funds, capital requirements, and financial market stability, all of which directly impact the trust's operations and performance.

Many innovative biotech and health tech companies start as small businesses, relying on R&D grants (like SBIR) and capital flow facilitated by the SBA, making this committee critical for early-stage health sciences investments.

Funding decisions by this committee directly impact government healthcare contractors and medical device manufacturers serving veterans, which are significant segments of the health sciences market.

Members receive classified briefings on global threats, including potential pandemics or bioweapons, which creates high risks for informational asymmetry in defense and biotech stocks – key components of the health sciences sector.